Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giuseppe Buono
Observed names:
G Buono,
G. Buono
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Baylor College of Medicine,
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori,
University of Naples Federico II
ORCID:
0000-0003-2829-1455
Observed ORCID:
0000-0003-2829-1455
OpenAlex ID:
A5102748330
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
2018
·
L. Gerratana
, D. Basile
, et al.
·
Cancer Treatment Reviews
·
320
PDF
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
2016
·
Francesco Schettini
, Giuseppe Buono
, et al.
·
Cancer Treatment Reviews
·
144
PDF
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
2019
·
Giuseppe Buono
, Lorenzo Gerratana
, et al.
·
Cancer Treatment Reviews
·
124
PDF
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
2018
·
Sabino De Placido
, Ciro Gallo
, et al.
·
The Lancet Oncology
·
108
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
2024
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Frontiers in Oncology
·
93
PDF
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
2020
·
Giuseppe Buono
, Anna Crispo
, et al.
·
Breast Cancer Research and Treatment
·
79
PDF
Burning Fog: Cognitive Impairment in Burning Mouth Syndrome
2021
·
Federica Canfora
, Elena Calabria
, et al.
·
Frontiers in Aging Neuroscience
·
54
PDF
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
2015
·
Grazia Arpino
, Carmine De Angelis
, et al.
·
Breast Cancer Research and Treatment
·
54
PDF
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
2019
·
Benedetta Conte
, Alessandra Fabi
, et al.
·
Clinical Breast Cancer
·
53
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis
2024
·
Francesco Schettini
, Sabrina Nucera
, et al.
·
Cancer Treatment Reviews
·
39
PDF
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
2022
·
Marianna Sirico
, Alessandra Virga
, et al.
·
Critical Reviews in Oncology/Hematology
·
38
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results
2018
·
Sabino De Placido
, Mario Giuliano
, et al.
·
The Breast
·
37
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
2023
·
Anna Crispo
, Livia S. A. Augustin
, et al.
·
Scientific Reports
·
26
PDF
Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
2017
·
Giuseppe Buono
, Anna Crispo
, et al.
·
Oncotarget
·
26
PDF
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom
2017
·
Francesco Schettini
, Giuseppe Buono
, et al.
·
Breast Care
·
25
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
2021
·
Grazia Lazzari
, Giuseppe Buono
, et al.
·
Breast Cancer Targets and Therapy
·
23
PDF
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
2021
·
F. Schettini
, B. Conte
, et al.
·
ESMO Open
·
22
PDF
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020
·
Margaret Ottaviano
, Marcello Curvietto
, et al.
·
Journal for ImmunoTherapy of Cancer
·
20
PDF
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
2022
·
Anna Diana
, Francesca Carlino
, et al.
·
Frontiers in Oncology
·
16
237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry
2023
·
G. Buono
, A. Deleuze
, et al.
·
ESMO Open
·
15
PDF
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study
2017
·
Giuseppe Buono
, Mario Giuliano
, et al.
·
Clinical Breast Cancer
·
14
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women
2016
·
A. Crispo
, M. Montella
, et al.
·
Current Research in Translational Medicine
·
13
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
2020
·
Salvatore Del Prete
, Liliana Montella
, et al.
·
Oncotarget
·
12
PDF
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
2022
·
Mariarosaria Saponaro
, Luigi Annunziata
, et al.
·
International Journal of Molecular Sciences
·
9
PDF
Show more works
View as search
Works count:
57
Citation count:
1,430
H-index:
19
I10-index:
24
Year
Topic
Type